MelliCell
Newton
About MelliCell
MelliCell develops technology that studies and uses fat cells to find new treatments for chronic diseases. The company focuses on creating fat cells in the lab to better understand how these cells affect health problems such as obesity, diabetes, and cancer. It uses a system called M3 technology to produce mature human fat cells that serve as models for medical research. These models help identify how fat cells release substances that may be useful for creating new treatments. The company works with other organizations to test and develop its technology for future medical use. MelliCell’s team includes scientists and advisors who study how fat cells can be used in medicine and surgery. The company continues to research and prepare new drug candidates for testing in clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.5M
- Funding stage: Seed
- Last round: Grant (Oct 2024)
- Website: mellicell.com
- Phone: +1-617-402-5551
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mellicell-61469 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.